Goodbody Health Inc. is the topic of conversation when DirectorsTalk Interviews Managing Director Darren Turgel caught up with Colin Smith, Director of Equity Research at Arden & Partners.
What has stood out in the FY2021 financial results?
The key points from the results were the strong progress with revenue up almost 9x YoY and a gross margin of 52%. Although headline earnings were impacted by a number of non-cash items, underlying cash generation was better than expected while cash and net cash ended the year at £6.1m with free cash flow generation of £1.7m.
What are some of the key areas of progress over the last year?
Goodbody Health continues to make good progress across its business lines including enhanced laboratory ISO certifications, sanction from the UK Food Standard Agency to move to the next stage of authorisation of the CBD product, continuation of the provision of Covid testing and, most importantly, expansion of the diagnostic services and blood testing offering that is being rolled out through partnering pharmacies, most notably Superdrug.
Does Goodbody Health represent a buying opportunity for investors?
Goodbody is making strong progress in its development beyond Covid testing toward in-pharmacy diagnostic services and blood testing which should see it become profitable this year with significant upside from its current trading level.
Goodbody Health Inc. are a wellness company, focusing on the Health and Wellness of customers through the local community by the introduction and use of cutting edge diagnostic equipment. Its is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF.
